Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000
Debt
Debt-to-Equity Ratio0.34
Current Ratio1.00
Quick Ratio0.85
Price-To-Earnings
Trailing P/E Ratio11.52
Forward P/E Ratio11.76
P/E Growth1.43
Sales & Book Value
Annual Sales$15.94 billion
Price / Sales4.08
Cash Flow$41.2888 per share
Price / Cash4.64
Book Value$207.19 per share
Price / Book0.92
Profitability
EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-10.29%
Return on Equity8.60%
Return on Assets5.23%
Miscellaneous
Employees17,800
Outstanding Shares339,440,000
Market Cap$63.16 billion
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan announced a quarterly dividend on Monday, July 30th. Shareholders of record on Friday, August 17th will be paid a dividend of $0.72 per share on Monday, September 17th. This represents a $2.88 dividend on an annualized basis and a yield of 1.51%. The ex-dividend date of this dividend is Thursday, August 16th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan announced that its board has authorized a stock repurchase plan on Tuesday, September 26th 2017, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) announced its quarterly earnings results on Thursday, July, 26th. The company reported $4.42 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $4.13 by $0.29. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $3.92 billion. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. Allergan's revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $4.02 EPS. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $16.00-16.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.08. The company issued revenue guidance of $15.45-15.6 billion, compared to the consensus revenue estimate of $15.31 billion.Allergan also updated its Q3 guidance to $3.80-4.10 EPS.
What price target have analysts set for AGN?
22 analysts have issued 1-year price objectives for Allergan's shares. Their forecasts range from $160.07 to $265.00. On average, they expect Allergan's stock price to reach $214.8535 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 5 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
- 2. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)
- 3. According to Zacks Investment Research, "2018 could prove to be a tough year for Allergan with the company facing loss of exclusivity for many products including Namenda XR and Restasis. Also, new competition for key growth drivers, Restasis and Linzess, is a concern. Nonetheless, Allergan boasts dominant growth franchises across several therapeutic areas. Key products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar will continue to support sales. Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018. Biosimilars also represent significant opportunity. In late 2017, Allergan announced cost-cutting efforts to protect it from potential revenue declines. Allergan’s share price has picked up after underperforming the industry in the second half of 2017. Estimates have gone up ahead of the Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/24/2018)
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX) and Zoetis (ZTS).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Has Allergan been receiving favorable news coverage?
Media headlines about AGN stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Allergan.
Who are Allergan's major shareholders?
Allergan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (1.73%), Edgewood Management LLC (1.69%), Janus Henderson Group PLC (1.41%), Northern Trust Corp (1.23%), Bank of New York Mellon Corp (1.05%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which major investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cantillon Capital Management LLC, Macquarie Group Ltd., Epoch Investment Partners Inc., Iridian Asset Management LLC CT, Swedbank, Point72 Asset Management L.P. and Jennison Associates LLC. View Insider Buying and Selling for Allergan.
Which major investors are buying Allergan stock?
AGN stock was purchased by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Mainstay Capital Management LLC ADV, Janus Henderson Group PLC, Orbimed Advisors LLC, Longview Partners Guernsey LTD, Wedge Capital Management L L P NC and Royal London Asset Management Ltd.. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $190.27.
How big of a company is Allergan?
Allergan has a market capitalization of $63.16 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
